Brokerages Anticipate Adamis Pharmaceuticals Corp (ADMP) to Post ($0.15) EPS

Shares of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) have earned a consensus broker rating score of 1.50 (Buy) from the two brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. Adamis Pharmaceuticals’ rating score has declined by 12.8% in the last 90 days as a result of a number of analysts’ upgrades and downgrades.

Analysts have set a 1-year consensus price target of $10.17 for the company and are predicting that the company will post ($0.15) EPS for the current quarter, according to Zacks. Zacks has also assigned Adamis Pharmaceuticals an industry rank of 156 out of 265 based on the ratings given to related companies.

A number of research analysts have commented on ADMP shares. Maxim Group set a $14.00 price objective on Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, December 5th. B. Riley set a $10.00 price objective on Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, November 30th. ValuEngine lowered Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, November 30th. Finally, Zacks Investment Research lowered Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 20th.

Institutional investors and hedge funds have recently made changes to their positions in the business. First Allied Advisory Services Inc. bought a new position in Adamis Pharmaceuticals in the 2nd quarter valued at $114,000. Bank of New York Mellon Corp boosted its position in Adamis Pharmaceuticals by 131.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 27,464 shares of the specialty pharmaceutical company’s stock valued at $143,000 after buying an additional 15,577 shares during the last quarter. Stonebridge Capital Advisors LLC boosted its position in Adamis Pharmaceuticals by 22.2% in the 2nd quarter. Stonebridge Capital Advisors LLC now owns 27,500 shares of the specialty pharmaceutical company’s stock valued at $143,000 after buying an additional 5,000 shares during the last quarter. Wells Fargo & Company MN bought a new position in shares of Adamis Pharmaceuticals in the 2nd quarter worth $169,000. Finally, Virtu KCG Holdings LLC boosted its position in shares of Adamis Pharmaceuticals by 103.2% in the 2nd quarter. Virtu KCG Holdings LLC now owns 38,474 shares of the specialty pharmaceutical company’s stock worth $200,000 after purchasing an additional 19,538 shares during the last quarter. Hedge funds and other institutional investors own 16.61% of the company’s stock.

Adamis Pharmaceuticals (NASDAQ:ADMP) traded down $0.03 during mid-day trading on Friday, reaching $4.43. The company had a trading volume of 364,891 shares, compared to its average volume of 523,601. Adamis Pharmaceuticals has a 12-month low of $2.80 and a 12-month high of $6.45. The company has a quick ratio of 3.79, a current ratio of 3.93 and a debt-to-equity ratio of 0.06.

COPYRIGHT VIOLATION NOTICE: This story was originally published by Stock Observer and is owned by of Stock Observer. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.thestockobserver.com/2018/01/13/brokerages-anticipate-adamis-pharmaceuticals-corp-admp-to-post-0-15-eps.html.

Adamis Pharmaceuticals Company Profile

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Get a free copy of the Zacks research report on Adamis Pharmaceuticals (ADMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply